| Autor: |
Saraiva TES; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., Rodrigues GZP; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., Kayser JM; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., Dallegrave E; Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil., Maus NP; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., Veiverberg A; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., Berna GDC; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., Schuster AC; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., de Freitas MG; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., Pitta MGDR; Research Centre for Therapeutic Innovation, Federal University of Pernambuco, Recife, Pernambuco, Brazil., Pitta IDR; Research Centre for Therapeutic Innovation, Federal University of Pernambuco, Recife, Pernambuco, Brazil., Gehlen G; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil., Betti AH; Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil. |
| Abstrakt: |
Schizophrenia is a psychiatric disorder that affects 1% of the world population and is treated with antipsychotics, which may induce important biochemical and hematological alterations. Since it is necessary to verify the safety of new molecules with antipsychotic potential, the present study aimed to evaluate the oral toxicity of PT-31, a putative α 2 -adrenoreceptor agonist, after acute (2000 mg/kg) and repeated doses (28 days) gavage treatment, in three different doses: minimum effective dose in animal models (10 mg/kg), twice the dose (20 mg/kg), and four times the dose (40 mg/kg), as recommended by the OECD guidelines. Balb/C female adult mice were used, and biochemical, hematological, and histopathological analyses were performed. PT-31 10 and 20 mg/kg did not cause biochemical alterations related to hepatic and renal toxicity, and neither altered glycemic and lipid profiles. The preclinical dose of PT-31 also did not promote mice histopathological changes in the liver, kidney, and brain. In the hematimetric parameters, PT-31 only increased HGB at 20 mg/kg, and MCH and MCHC at 40 mg/kg. However, all the tested doses of PT-31 showed platelet increase, which must be better investigated. Therefore, further studies are needed to investigate the safety of PT-31 as a potential antipsychotic drug. |
